J&J says its single dose protects against breakthrough Covid-19 for up to 6 months

    Published Thu, Jan 6, 2022 · 11:21 PM

    [BENGALURU] Johnson & Johnson said on Thursday that a real-world study showed its single shot Covid-19 vaccine protects against breakthrough infections and hospitalisations for up to six months.

    The study, sponsored by the vaccine developer, was conducted between Jan 1 and Sept 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.

    J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna.

    No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

    The company said the study was carried out by collecting claims and laboratory data covering 168 million people.

    REUTERS

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    Share with us your feedback on BT's products and services